DNMT3A and acute myeloid leukemia: We confirmed elevated expression of repetitive elements and ISGs in our DNMT3A-mutant AML samples (Extended Data Fig. 7h,i), suggesting that activity of an already elevated IFN pathway may sensitize the responsiveness of patient cells to further pathway activation induced by combo treatment.